News & Updates

The monoclonal antibody pamrevlumab does not appear to improve outcomes for patients with idiopathic pulmonary fibrosis when compared with placebo, according to the phase III ZEPHYRUS-1 trial.

In the treatment of patients with interstitial lung disease (ILD) and early-stage non–small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) has met the prespecified acceptability thresholds for both toxicity and efficacy, according to the single-arm, phase II ASPIRE-ILD study.

The use of bisoprolol does not appear to yield reductions in the number of self-reported chronic obstructive pulmonary disease (COPD) exacerbations requiring treatment with oral corticosteroids, antibiotics, or both, as shown in the placebo-controlled Bisoprolol in COPD Study (BICS).

Individuals who regularly eat ultra-processed foods are at greater risk of death, which is driven by causes other than cancer and cardiovascular diseases (CVD), reports a study.

Patients with chronic obstructive pulmonary disease (COPD) face an increased risk of secondary spontaneous pneumothorax, as reported in a study from Taiwan.

Treatment with dupilumab significantly reduced the annual rate of severe exacerbations in children with uncontrolled, moderate-to-severe type 2 asthma who were on high- or medium-dose inhaled corticosteroid (ICS), according to a study presented at PAS 2024.

For women with cystic fibrosis, multiple pregnancies lead to higher rates of preterm births and faster respiratory decline, according to a retrospective cohort study.